A new study from Stanford University's School of Medicine and the Lucile Packard Children's Hospital Stanford shows that an asthma drug may accelerate the process of allergen desensitization in patients undergoing treatment.
The study, which follows another study just released from Stanford looking at multiple food allergies being treated simultaneously, was also a phase-1 safety trial, giving evidence of efficacy.
Drug accelerates desensitization process
The study found that patients who took the asthma drug omalizumab were desensitized to multiple food allergens at a median of 18 weeks, while those who did not take the drug had a median of 85 weeks. The results of the study were published in the journal Allergy, Asthma & Clinical Immunology.
In the most recent study in this series, the second so far, 25 children and adults with multiple food allergies underwent a desensitization process which began with injections of omalizumab eight weeks prior to the desensitization. The drug is used for severe allergy sufferers and reduces IgE molecule activity, which are the molecules an allergic responses. Patients who underwent this regimen were able to tolerate larger doses of allergens from the beginning of the desensitization process, allowing them to progress faster.